Literature DB >> 34458736

The medicinal chemistry of mitochondrial dysfunction: a critical overview of efforts to modulate mitochondrial health.

Maximillian Taro William Lee1, William Mahy1, Mark David Rackham1.   

Abstract

Mitochondria are subcellular organelles that perform a variety of critical biological functions, including ATP production and acting as hubs of immune and apoptotic signalling. Mitochondrial dysfunction has been extensively linked to the pathology of multiple neurodegenerative disorders, resulting in significant investment from the drug discovery community. Despite extensive efforts, there remains no disease modifying therapies for neurodegenerative disorders. This manuscript aims to review the compounds historically used to modulate the mitochondrial network through the lens of modern medicinal chemistry, and to offer a perspective on the evidence that relevant exposure was achieved in a representative model and that exposure was likely to result in target binding and engagement of pharmacology. We hope this manuscript will aid the community in identifying those targets and mechanisms which have been convincingly (in)validated with high quality chemical matter, and those for which an opportunity exists to explore in greater depth. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34458736      PMCID: PMC8372206          DOI: 10.1039/d1md00113b

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  217 in total

1.  Dimethyl Fumarate Protects Brain From Damage Produced by Intracerebral Hemorrhage by Mechanism Involving Nrf2.

Authors:  Xiurong Zhao; Guanghua Sun; Jie Zhang; Shun-Ming Ting; Nicole Gonzales; Jaroslaw Aronowski
Journal:  Stroke       Date:  2015-05-14       Impact factor: 7.914

2.  DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis.

Authors:  Xinhong Feng; Ying Peng; Mingsheng Liu; Liying Cui
Journal:  Neuropharmacology       Date:  2011-11-02       Impact factor: 5.250

Review 3.  Role of PGC-1α in Mitochondrial Quality Control in Neurodegenerative Diseases.

Authors:  Qi Zhang; Yu-Hong Lei; Jue-Pu Zhou; Ye-Ye Hou; Zheng Wan; Hong-Lei Wang; Hao Meng
Journal:  Neurochem Res       Date:  2019-08-13       Impact factor: 3.996

4.  A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas.

Authors:  Jana Portnow; Behnam Badie; Susan Markel; An Liu; Massimo D'Apuzzo; Paul Frankel; Rahul Jandial; Timothy W Synold
Journal:  Eur J Cancer       Date:  2013-02-04       Impact factor: 9.162

5.  Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

Authors:  Ling-Hui Zeng; Lin Xu; David H Gutmann; Michael Wong
Journal:  Ann Neurol       Date:  2008-04       Impact factor: 10.422

6.  Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.

Authors:  Chi B Vu; Jean E Bemis; Jeremy S Disch; Pui Yee Ng; Joseph J Nunes; Jill C Milne; David P Carney; Amy V Lynch; Jesse J Smith; Siva Lavu; Philip D Lambert; David J Gagne; Michael R Jirousek; Simon Schenk; Jerrold M Olefsky; Robert B Perni
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

7.  Crystallographic structure of a small molecule SIRT1 activator-enzyme complex.

Authors:  Han Dai; April W Case; Thomas V Riera; Thomas Considine; Jessica E Lee; Yoshitomo Hamuro; Huizhen Zhao; Yong Jiang; Sharon M Sweitzer; Beth Pietrak; Benjamin Schwartz; Charles A Blum; Jeremy S Disch; Richard Caldwell; Bruce Szczepankiewicz; Christopher Oalmann; Pui Yee Ng; Brian H White; Rebecca Casaubon; Radha Narayan; Karsten Koppetsch; Francis Bourbonais; Bo Wu; Junfeng Wang; Dongming Qian; Fan Jiang; Cheney Mao; Minghui Wang; Erding Hu; Joe C Wu; Robert B Perni; George P Vlasuk; James L Ellis
Journal:  Nat Commun       Date:  2015-07-02       Impact factor: 14.919

8.  Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates.

Authors:  Scott A Reisman; Sarabjit S Gahir; Chun-Yue I Lee; Joel W Proksch; Mitsumasa Sakamoto; Keith W Ward
Journal:  Drug Des Devel Ther       Date:  2019-04-17       Impact factor: 4.162

9.  Improvement of pharmacokinetics behavior of apocynin by nitrone derivatization: comparative pharmacokinetics of nitrone-apocynin and its parent apocynin in rats.

Authors:  Kaiyu Wang; Linlin Li; Yan Song; Xiaocui Ye; Shaolian Fu; Jie Jiang; Sha Li
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

10.  c-Abl and Parkinson's Disease: Mechanisms and Therapeutic Potential.

Authors:  Saurav Brahmachari; Senthilkumar S Karuppagounder; Preston Ge; Saebom Lee; Valina L Dawson; Ted M Dawson; Han Seok Ko
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.